Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Sakigake Tag Withdrawn for 2 Boehringer Drugs
The Ministry of Health, Labor and Welfare (MHLW) said on February 19 that it has withdrawn the sakigake fast-track designation for two drugs by Nippon Boehringer Ingelheim, brigimadlin and nerandomilast.Brigimadlin had been designated for the proposed indication of advanced or…
To read the full story
REGULATORY
- Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
April 9, 2026
- Chuikyo Sets Reimbursement Pathways for Five Regenerative Medicine Products
April 9, 2026
- Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
- Chuikyo Names Hosei Prof. Sugahara to Drug Pricing, CEA Panels
April 9, 2026
- MHLW Publishes Updated LLP List with Higher Surcharges from June
April 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…